• GlaxoSmithKline Vaccine HPV-007 Study Group, B Romanowski, P Colares de Borba, P S Naud, C M Roteli-Martins, N S De Carvalho, J C Teixeira, F Aoki, B Ramjattan, R M Shier, R Somani, S Barbier, M M Blatter, C Chambers, D Ferris, S A Gall, F A Guerra, D M Harper, J A Hedrick, D C Henry, A P Korn, R Kroll, A-B Moscicki, W D Rosenfeld, B J Sullivan, C S Thoming, S K Tyring, C M Wheeler, G Dubin, A Schuind, T Zahaf, Mary Greenacre, and An Sgriobhadair.
• University of Alberta, 1000-8215 112 Street, Edmonton, AB, Canada, T6G 2C8. broman@docromanowski.com
• Lancet. 2009 Dec 12;374(9706):1975-85.

BackgroundProphylactic human papillomavirus (HPV) vaccines have to provide sustained protection. We assessed efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years.MethodsWomen aged 15-25 years, with normal cervical cytology, who were HPV-16/18 seronegative and oncogenic HPV DNA-negative (14 types) at screening participated in a double-blind, randomised, placebo-controlled initial study (n=1113; 560 vaccine group vs 553 placebo group) and follow-up study (n=776; 393 vs 383). 27 sites in three countries participated in the follow-up study. Cervical samples were tested every 6 months for HPV DNA. Management of abnormal cytologies was prespecified, and HPV-16/18 antibody titres were assessed. The primary objective was to assess long-term vaccine efficacy in the prevention of incident cervical infection with HPV 16 or HPV 18, or both. We report the analyses up to 6.4 years of this follow-up study and combined with the initial study. For the primary endpoint, the efficacy analysis was done in the according-to-protocol (ATP) cohort; the analysis of cervical intraepithelial neoplasia grade 2 and above (CIN2+) was done in the total vaccinated cohort (TVC). The study is registered with ClinicalTrials.gov, number NCT00120848.FindingsFor the combined analysis of the initial and follow-up studies, the ATP efficacy cohort included 465 women in the vaccine group and 454 in the placebo group; the TVC included 560 women in the vaccine group and 553 in the placebo group. Vaccine efficacy against incident infection with HPV 16/18 was 95.3% (95% CI 87.4-98.7) and against 12-month persistent infection was 100% (81.8-100). Vaccine efficacy against CIN2+ was 100% (51.3-100) for lesions associated with HPV-16/18 and 71.9% (20.6-91.9) for lesions independent of HPV DNA. Antibody concentrations by ELISA remained 12-fold or more higher than after natural infection (both antigens). Safety outcomes were similar between groups: during the follow-up study, 30 (8%) participants reported a serious adverse event in the vaccine group versus 37 (10%) in the placebo group. None was judged related or possibly related to vaccination, and no deaths occurred.InterpretationOur findings show excellent long-term efficacy, high and sustained immunogenicity, and favourable safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years.FundingGlaxoSmithKline Biologicals (Belgium).

19 keywords...

hide…